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ABSTRACT 
NSAIDs suffer from a serious drawback of GI-SEs caused particularly after chronic use. There is evidence concerning the 
participation of ROS in the etiology & pathophysiology of digestive system disorders like GI-inflammation & gastro ulcer. With the 
aim to retard the adverse effects of GI-Origin, conjugates of NSAIDs (especially the carboxylic acid derivatives) with some 
antioxidants can be synthesized by esterification with various antioxidants of natural origin. The conjugates that show the retention 
or potentiating of anti-inflammatory activity with reduced ulcerogenic side effect could be potential gastroprotective co-drugs of 
NSAIDs. 
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Inflammation is defined as the changes occurring in-
response to tissue injury, infection or presence of foreign 
substance and it is a part of host defense mechanism 
characterized by redness, pain & swelling at the site. 
Inflammation leads to damage of cell membrane, which 
causes leukocytes to release lysosome enzymes & cause 
several events called Arachidonic acid cascade 
1
. There 
are various cells like neutrophils, basophils, 
macrophages, monocytes, mast cell, platelets, 
lymphocytes, monocytes etc. Which release various 
inflammatory mediators and modulators like 
Arachidonic 
Acid metabolites, leukotrienes, Thromboxane, Platelet 
activating factors lysosomal enzymes, histamine, 
serotonin as well as various reactive oxygen species 
1
. 
The release of chemical compounds and compression of 
the nerves(due to swelling/oedema) in the vicinity of the 
inflammation causes pain 
1
. Inflammation is mediated by 
several families of mediators among these the 
Eicosanoids i.e. the lipid mediators produced from 
Arachidonic acid cascade are moststudied. The 
eicosanoids include 
 (1) prostanoids i.e. Prostaglandins formed through 
cyclooxygenase pathway,  
(2) Lipoxygenase pathway products like Leukotrienes, 
lipoxins, hepoxillins . 
(3) Cyt.P450 pathway products like epoxy fatty acids 
and dihydroxyl fatty acids 




ANTI-INFLAMMATORY DRUGS  
The substances that inhibit the important sign of 
inflammation like redness, pain & swelling are called 
anti-inflammatory drugs. These may be either steroidal 
or non-steroidal anti-inflammatory drugs. Steroidal anti-
inflammatory act by inhibit the synthesis of both 
eicosanoids and PAF while NSAIDs act by inhibiting 
the synthesis of mainly eicosanoids 
2
. 
The NSAIDs are the drugs used most commonly for 
their analgesic, antipyretic, anti-inflammatory & 
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antithrombogenic effects. Their specific use includes the 
treatment of headache, toothache, body ache, arthritis, 
ankylosing spondylitis, sports injuries, etc. It is the most 
widely used class of drugs world over for example in 
U.S alone out of approximately $30 billion per year drug 
costs 25% i.e. $56.11 is on NSAIDs. But the NSAIDs 
are called silent epidemic as around 107,000 
hospitalizations and MT 16,500 deaths annually are 
reported in UK alone due to complications due to GI 
side effects of NSAIDs. The NSAIDs showed increased 
risk of renal & CV complications but the most common 
& dangerous of these side effects are related to GI 
disturbance and occurrence of these GI-SEs may 
sometimes be such great that it leads to patient non-
compliance and even discontinuation of therapy. The 
fact that both the pharmacological action (i.e. analgesic, 
anti-inflammatory) and the side effects of NSAIDs are 
linked to their property of inhibition of synthesis of 
prostaglandins. It is confirmed that prostaglandins have 
both beneficial action and inflammatory mediator 
actions. 
Ideally the NSAIDs should inhibit PG-synthesis at the 
sites of inflammation only hence produce the desired 
anti-inflammatory analgesic / or antipyretic action. In 
fact the NSAIDs start their action in GIT also, their most 
common route of administration. But in GIT the 
Prostaglandins play an important role of maintaining the 
homeostasis i.e. has a beneficial effect. The examples of 
beneficial effects of prostaglandins in GIT are: 
1) Bicarbonate secretion  
HCO3 are formed from the surface epithelial cells of 
gastroduodenal epithelium and are secreted into the 
mucus layer which covers it. PGE2 is the major 
eicosanoid which stimulates the gastric bicarbonate 
secretion but NSAIDs are potential inhibitors of PGE2 
synthesis especially in GI-epithelium as NSAIDs stay 
longer in GI-epithelial cells due to the NSAIDs- ionic 
trapping phenomenon causing prolonged inhibition of 
PG-production in the digestive tract. The mucus 
bicarbonate layer is an important line of defense in GIT 
against the damaging effects of gastric acid, pepsin or 
other aggressive factors like proteases, H.pylorioxidative 
stress etc. and thereby provides the apical membrane of 
the surface epithelial cells with a near neutral pH milieu 
2
. 
2) Mucus Secretion 
Gastric mucus, a viscous gel that coats the entire gastric 
mucosa is produced by & secreted from the surface 
epithelial cells. Topical prostaglandins, dimethylPGE2, 
PGF2& carbenoxolone have been observed to increase 




GMSH i.e. gastric mucosal surface hydrophobicity is 
essential component of mucosal defense system that is 
decreased by NSAIDs 
2
. 
4) Back-diffusion of H+ 
The removal of back-diffused H-ions through the 
microcirculatory flow is an important aspect of GI-
defense against the gastric acid. This microcirculation in 
GIT is also regulated by prostaglandins secreted locally. 
NSAIDs by PG-synthesis inhibition action breaks this 
mucosal protection defense further adding to ulcerogenic 
side effect of NSAIDs. 
5) Generation of reactive oxygen species 
Oxidative stress plays an important role in tissue injury. 
It has been observed that if the prooxidant conditions 
predominates due to increased generation of reactive 
oxygen species or due to poor or weakened antioxidant 
inbuilt mechanism leading to oxidative stress in the 
tissue and there are experimental evidences supporting 
the fact that the ulcerogenic effect of NSAIDs are 
mediated by reactive oxygen species 
4
. 
 Thus NSAIDs produce lesions in the GIT by 
1) Direct inhibition action, a physicochemical 
phenomenon, due to their acidic nature (i.e. naked 
carboxylic acid group) 
2) Prostaglandin synthesis inhibition action by 
inhibiting cyclooxygenases, a pharmacological 
phenomenon, hence inhibiting the local synthesis 
and secretion & protective mucus as well as 
bicarbonate ions in GIT. 
3) By prolonged stay inside the GI-epithelial cells, a 
biochemical phenomenon, by ‘NSAIDs-ionic 
trapping’. 
4) By causing thrombosis in microcirculation & 
vasoconstriction of arterioles of submucosa. 
5) By delayed ulcer healing, an indirect phenomenon 
as the prostaglandins play a key role in ulcer 
healing, while inhibition of endogenous PG-
synthesis in GIT by NSAIDs results in delayed ulcer 
healing. 
6) By generation of ROS which have direct damaging 
effect. 
GI-DISEASE AND ROLE OF ROS  
There is enough experimental and clinical evidence 
which shows the role of various ROS in NSAIDs 
induced GI-ulceration 
5
 NSAIDs produce the prooxidant 
environment i.e. oxidative stress in GIT. 
NSAIDs and generation of ROS-oxidative stress 
Oxidative stress plays an important role in tissue injury. 
It has been observed that if the pr0oxidant conditions 
predominate either due increased generation of ROS or 
due to poor, weakened antioxidant inbuilt mechanism it 
leads to oxidative stress in the tissue. 










), and nitric oxide (NO
.
). These ROS are the free 
radicals which are extremely short lived, highly reactive 
moiety carrying an unpaired electron, always in attempt 
to attack other molecule to acquire an electron to pair its 
unpaired electron. These other molecules may be lipids, 
proteins, nucleic acids resulting in damages to 
biomolecules constituting cell membranes, organelles, 
DNA, RNA etc. 
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Oxygen is vital for aerobic life processes and 
approximately 5% of the inhaled O2 is converted to 
various ROS by univalent reduction of O2 
6
. In fact all 
reactive oxygen species are generated from oxygen. 
ROS is a collective term that includes both radicals and 
non-radical species participating in initiation or 
propagation reactions. These free radicals are generated 
continuously from the oxygen consumed in respiration; 
cell mediated inflammatory and immune processes. 
Normally there is a balance between the number of free 
radicals/ROS generated in our body and the number of 
defensive scavengers for these reactive oxygen species 
thus protecting us from the deterrent effects of these 
reactive species. These reactive species in search of 
pairing their unpaired electron attack the vital 
biomolecules like DNA, proteins etc. Thus damaging bio 
membranes like those of mitochondria, eventually 
causing cells to lose their structure and/or function and 
ultimately in cell death. Various necrotic factors, 
protease and ROS from the damaged cells also attack the 
surrounding cells, resulting ultimately in tissue & organ 
injury. When the balance between the number of ROS 
generated and the number of ROS-
scavengers/antioxidants in biological system in towards 
more generation than neutralization then this state is 
called “Oxidant stress” which results in tissue injury and 
subsequent diseases. In case of prolonged therapy with 
NSAIDs as in case of treatment of rheumatoid arthritis, 
osteoarthritis and other chronic inflammatory conditions 
etc. There is strong evidence that NSAIDs induced GI 
ulcerations, lesions are due to excessive oxidant stress. 
NSAIDs like indomethacin induce micro vascular injury 
in gastric mucosa and the reports suggest that the 
inhibition of prostaglandin synthesis was unlikely to be 
the sole mechanism responsible for gastric injuries 
induced by NSAIDs induced gastric ulceration is well 
studied where it reported that the excessive generation of 
oxygen radicals in extracellular spaces and depletion of 
GSH in conjunction with inhibition of glutathione 
peroxidase activity 
8
 is responsible for oxidative tissue 
damage of gastric mucosa after prolonged administration 
of NSAIDs (indomethacin, Ibuprofen, Aspirin etc.). The 
vulnerability of various bio membranes to various ROS 
is due to presence of PUFAs, like arachidonic acid, 
linoleic acid, linolenic acids in the form of esters with 
cholesterols, phospholipids or triglycerides. The 
proteins, nucleic acids and carbohydrates are less 
responsible to free radical attacks induced membrane 
injuries. 
Defenses against ROS-Antioxidant defenses 
 An antioxidant is a substance which reduces or delays 
oxidation of oxidizable substrate by themselves getting 
oxidized in comparison to the substrates. Human body 
has endogenously produced antioxidants which protect 
the body from damaging ROS/ free radicals produced by 
various biochemical reactions, environmental pollutants, 
irradiations, or in this case produced by chronic use of 
NSAIDs as in cases of rheumatoid arthritis, 
osteoarthritis, ankylosing spondylitis etc. The various 
endogenous sources of antioxidant can be following: 
1. Enzymatic for example superoxide dismutase 
(SOD), catalases (CAT), glutathione peroxidase 
(GPx) 
9
, cytochrome C oxidase etc. 
2. No enzymatic antioxidants for example the low 
molecular weight non-enzymatic agents synthesized 
in the body acting as free radical scavenger like 
bilirubin, α-keto acid, sex hormones, melatonin, 
lipoic acid, coenzymes, uric acid, histidine 
containing peptides, etc. 
3. Dietary sources like vitamin C, vitamin E, various 
categories of natural colored pigments (like yellow, 
orange, red pigments as in mangoes, carrot, 
tomatoes, turmeric, etc.), plant phenols as 
flavonoids, anthocyanidins, phenylpropanoids. 
These endogenously produced antioxidants protect 
the body from damaging oxidation reactions. But 
these endogenous antioxidant supply is limited and 
there is a need to replenish antioxidant resources 
either endogenously or through supplementation 
especially in situation of oxidative stress in the 
tissues for example in gastric ulcers happening most 
commonly after chronic use of NSAIDs 
11
 
The NSAIDs induced GI side effects include nausea, 
vomiting, abdominal pain, mucosal lesions, serious 
complications like bleeding, perforation etc. It is clear 
that GI-discomfort and hence the poor patient 
compliance are the major limitations of NSAIDs 
therapy. Hence some gastro protective NSAIDs should 
be designed for which various strategies can be adopted 
as: 
1) Mask the naked acid (carboxylic acid) group of 
NSAIDs so that the local irritant action is removed 
i.e. covert the acid into ester or amides. 
2) The acid/amide formed should be such that it does 
not release the NSAID inside GIT or get trapped in 
the GI-epithelial cells but carries it to the desired 
site of action col inflammation where it releases the 
free NSAID. 
3) Co-administration of NSAIDs and antioxidants 
Based on the above facts it is suggested that to prevent 
gesture-ulceration, etc. caused due to chronic/acute use 
of NSAIDs, the co-administration of NSAIDs with 
antioxidants will be suitable. There are various classes of 
antioxidants. 
Mechanism of action of ROS, free radicals-lipid 
peroxidation   






, or others ROS 
extract a hydrogen atom from a PUFA (of bio 
membranes) a carbon centered lipid radical is produced. 
This is followed by the addition of oxygen to lipid 
radical to form lipid derived free radicals for example 
lipid peroxy radicals, lipids hydroperoxyl radicals, 
conjugated dienes.) These propagate the chain reaction 
by extracting H-atom from nearby PUFA. The resulting 
lipid hydroperoxide easily decomposes to form lipid 
alkoxyl radicals (LO
.
) as shown in figure: 
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Initiation: 
 
The chain reaction continues (damaging the cell membrane) till some antioxidant interrupts it through scavenging the 




Hence some gastroprotective NSAIDs should be 
designed for which various strategies can be there: 
1) Mask the naked acid (carboxylic acid) group of 
NSAIDs. so that the local irritant action is removed 
i.e. convert the acid into ester or amides. 
2) The acid/amide formed should be such that it does 
not release the NSAIDs inside GIT or get trapped in 
the GI-epithelial cells but carries to the desired site 
of action. Col inflammation where releases the free 
NSAIDs. 
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